Novartis Ag (NVS) Total Debt (2009 - 2026)
Novartis Ag (NVS) posted Total Debt of $47.1 billion for Q2 2026, up 247873.68% sequentially from -$19.0 million in Q1 2026, and up 52.93% YoY from $30.8 billion in Q2 2025.
Novartis Ag (NVS) Total Debt (2009 - 2026) Analysis & Trends
Novartis Ag has reported Total Debt for 18 years, with the latest figure at $47.1 billion in Q2 2026.
- Quarterly Total Debt rose 52.93% year-over-year to $47.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $47.1 billion (up 52.93% YoY) and the FY2025 annual result came in at $33.5 billion, up 13.31% from the prior year.
- Total Debt grew to $47.1 billion in Q2 2026 per NVS's latest filing, from -$19.0 million in the prior quarter.
- Over five years, Total Debt peaked at $47.1 billion in Q2 2026 and troughed at -$19.0 million in Q1 2026.
- A 5-year average of $24.2 billion and a median of $26.5 billion in 2023 frame the typical range for Total Debt.
- The sharpest annual moves came in 2022 and 2025: Total Debt decreased 13.64% in 2022, then jumped 57.04% in 2025.
- Over 5 years, Total Debt stood at $26.2 billion in 2022, then retreated by 5.98% to $24.6 billion in 2023, then fell by 13.23% to $21.4 billion in 2024, then surged by 57.04% to $33.5 billion in 2025, then surged by 40.37% to $47.1 billion in 2026.
- According to Business Quant data, Total Debt over the past three periods registered $47.1 billion, -$19.0 million, and $33.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 49.04 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 70.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 53.91 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 29.49 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 62.75 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 28.66 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 63.19 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -25.96 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 25.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.08 Bn |
| Mar 31, 2026 | -19.00 Mn |
| Dec 31, 2025 | 33.54 Bn |
| Sep 30, 2025 | -9.00 Mn |
| Jun 30, 2025 | 30.78 Bn |
| Dec 31, 2024 | 21.36 Bn |
| Jun 30, 2024 | 27.20 Bn |
| Dec 31, 2023 | 24.61 Bn |
| Jun 30, 2023 | 26.55 Bn |
| Dec 31, 2022 | 26.18 Bn |
| Jun 30, 2022 | 29.28 Bn |
| Dec 31, 2021 | 29.20 Bn |
| Jun 30, 2021 | 33.90 Bn |
| Dec 31, 2020 | 36.04 Bn |
| Jun 30, 2020 | 32.83 Bn |
| Dec 31, 2019 | 27.38 Bn |
| Jun 30, 2019 | 28.22 Bn |
| Mar 31, 2019 | 338.00 Mn |
| Dec 31, 2018 | 32.15 Bn |
| Jun 30, 2018 | 32.36 Bn |